Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease by unknown
RESEARCH Open Access
Structural studies on molecular mechanisms of
Nelfinavir resistance caused by non-active site
mutation V77I in HIV-1 protease
Ankita Gupta1, Salma Jamal2, Sukriti Goyal2, Ritu Jain3, Divya Wahi3, Abhinav Grover3*
From Brazilian Symposium on Bioinformatics 2014
Belo Horizonte, Brazil. 28-30 October 2015
Abstract
Background: The human immunodeficiency virus (HIV-1) is a retrovirus causing acquired immunodeficiency
syndrome (AIDS), which has become a serious problem across the world and has no cure reported to date. Human
immunodeficiency virus (HIV-1) protease is an attractive target for antiviral treatment and a number of therapeutically
useful inhibitors have been designed against it. The emergence of drug resistant mutants of HIV-1 poses a serious
problem for conventional therapies that have been used so far. Until now, thirteen protease inhibitors (PIs), major
mutation sites and many secondary mutations have been listed in the HIV Drug Resistance Database. In this study,
we have studied the effect of the V77I mutation in HIV-PR along with the co-occurring mutations L33F and K20T
through multi-nanosecond molecular dynamics simulations. V77I is known to cause Nelfinavir (NFV) resistance in the
subtype B population of HIV-1 protease. We have for the first time reported the effect of this clinically relevant
mutation on the binding of Nelfinavir and the conformational flexibility of the protease.
Results: Two HIV-PR mutants have been considered in this study - the Double Mutant Protease (DBM) V77I-L33F
and Triple Mutant Protease (TPM) V77I-K20T-L33F. The molecular dynamics simulation studies were carried out and
the RMSD trajectories of the unliganded wild type and mutated protease were found to be stable. The binding
affinity of NFV with wild type HIV-PR was very high with a Glide XP docking score of -9.3 Kcal/mol. NFV showed
decreased affinity towards DBM with a docking score of -8.0 Kcal/mol, whereas its affinity increased towards TPM
(Glide XP score: -10.3). Prime/MM-GBSA binding free energy of the wild type, DBM and TPM HIV-PR docked
structures were calculated as -38.9, -11.1 and -42.6 Kcal/mol respectively. The binding site cavity volumes of wild
type, DBM and TPM protease were 1186.1, 1375.5 and 1042.5 Å3 respectively.
Conclusion: In this study, we have studied the structural roles of the two HIV-PR mutations by conducting
molecular dynamics simulation studies of the wild type and mutant HIV-1 PRs. The present study proposes that
DBM protease showed greater flexibility and the flap separation was greater with respect to the wild type protease.
The cavity size of the MD-stabilized DBM was also found to be increased, which may be responsible for the
decreased interaction of Nelfinavir with the cavity residues, thus explaining the decreased binding affinity. On the
other hand, the binding affinity of NFV for TPM was found to be enhanced, accounted for by the decrease in
cavity size of the mutant which facilitated strong interactions with the flap residues. The flap separation of TPM
was less than the wild type protease and the decreased cavity size may be responsible for its lower resistance, and
hence, may be the reason for its lower clinical relevance.
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Background
Human immunodeficiency virus type 1 (HIV-1), a mem-
ber of the retrovirus family, causes acquired immunodefi-
ciency syndrome (AIDS) which progressively destroys the
body’s natural immune system leading to deadly infec-
tions and cancers [1]. According to the World Health
Organization (WHO), HIV has affected 35 million people
so far and continues to be a major public health burden
globally, with 69% of the population affected alone in
sub-Saharan Africa [2,3]. The current therapeutic options
available include highly active antiretroviral therapy
(HAART) combination, a set of antiretroviral drugs
which inhibit the replication of virus in the body and
reduce the burden of the disease, but drugs or vaccines
which can eradicate the viruses from the human body
still remain a question to be addressed [4]. Additionally,
the existing antiretroviral drugs are very expensive and
are associated with the risk of non-AIDS disorders that
include cardiovascular, liver, kidney and neurological dis-
ease [5]. Owing to the huge global burden of the disease,
the lack of effective drugs and vaccines which can kill the
pathogen, the high costs and the serious side effects
related to the existing drugs and the accumulating drug
resistance has made the search for anti-HIV drugs a fore-
most research priority.
HIV-1 proliferates with the support of its own homo-
dimeric aspartic protease, an enzyme essential for viral
replication and assembly, also referred to as HIV-1 pro-
tease (HIV-1 PR) [2]. HIV1-PR is a homodimer of a 99
amino acid long sequence that forms C2 symmetry in
the absence of the natural substrate or ligand [3]. The
dimer interface forms the active site of the enzyme,
which have two catalytic aspartic acid residues. The
function of protease is assisted by the characteristic flap
movement which provides restricted access to the active
site. The flaps are flexible, antiparallel, glycine-rich
b-sheets made of residues 45-55 from both the chains of
the homodimer (Figure 1B) [4-6]. From X-ray crystallo-
graphic studies it is known that there are consistent
structural differences between the bound and free-state
of the protein. The flaps adopt a semi-open conforma-
tion in the unbound state, whereas they are pulled into
the active site to form a closed structure in the bound
state [7,8]. The recognition of HIV-1 PR as a major tar-
get for antiviral therapy has led to determination of its
large number of structures with slight sequence
Figure 1 (A) Structure of double mutated protease: DBM. Mutated residues V77I and L33F are shown in yellow. (B) Crystal structure of HIV-1
PR. (C) Structure of triple mutated protease: TPM. Mutated residues V77I, L33F and K20T are shown in yellow. (D) DBM superimposed on wild
type HIV-1 PR. (E) TPM superimposed on wild type HIV-1 PR. Difference between wild and mutants is highlighted using arrows and circles. The
superimposed structure are further magnified to view the side chains.
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variations and different ligands. HIV-1 PR cleaves the
nonfunctional polyproteins that include gag and pol
proteins, reverse transcriptase, integrase, and protease
itself, and is responsible for creating the mature and
functional components of the protein [9].
Functional inhibition of HIV-1 PR leads to incomplete
viral replication and therefore makes it an attractive target
for anti-HIV drugs [3]. To date, seven protease inhibitors
(PIs) have been approved by the U.S. Food and Drug
Administration [10]. However, emergence of several resis-
tant viral species due to genetic mutations in active and
non-active sites of HIV-1 PR has made the current thera-
pies inefficient and inappropriate for use. The active site
mutations also referred to as primary mutations cause
direct resistance, while the secondary mutations often
accompany primary mutations (accessory mutations) or
they show synergistic resistance in the presence of other
secondary mutations [11]. These mutations are a conse-
quence of the selective pressure rising due to antiviral
agents. Another driving force of the resistance causing
mutations is the recently reported immunological pressure
and the mutations are described as ‘Escape mutations’ [12].
V77I is one of the important non active site secondary
mutations in HIV-PR, causing resistance against Nelfina-
vir (NFV). It is a highly polymorphic mutation present
near the cheek sheet of protease, with a marked presence
in subtype B virus. This minor mutation is accompanied
by other primary and secondary mutations [13]. L33F is a
major mutation present in the active site of the protease
[14], which results in reduced susceptibility towards NFV
in the presence of other mutations. It is a non-poly-
morphic mutation which provides resistance against all
PIs except Indinavir and Saquinavir. L33I is a less com-
monly occurring mutation with similar effects to L33F,
while L33V mutation has not been related to any kind of
drug resistance in PI therapy. L33F co-occurs with V77I
in large number of HIV-1 subtype B infected patient
samples, as reported in Stanford’s HIV Drug Resistance
Database [13]. The mutation at the 20th residue is
another non-polymorphic site present in the cheek turn
and is involved in rendering resistance against all PIs
except Saquinavir and Tipranavir. K20T is the most pro-
minent mutation occurring at the 20th residue [15] and
has been found to co-occur with V77I in subtype B popu-
lation. It is interesting to note that the 77th, 33rd and 20th
amino acids form a set of residues interacting with the
36th residue of the protease, which itself is present on
non-active site and its mutation causes resistance to NFV
in non-subtype B viruses [16]. L23I, D30N, E35G, M46I/
L/V, G48V, I54L, G73S/T/C/A, T74S, V82A/F/S/T, I84V,
N88D/S and L90M are other mutations correlated to
NFV resistance.
In the present study, we have scrutinized the behavior
of the minor mutation V77I along with co-occurring
mutations L33F and K20T and have considered the two
types of mutants, a double mutant, V77I-L33F (DBM)
and a triple mutant, V77I-L33F-K20T (TPM); according
to their actual prevalence [13] (Table 1). The other
mutations which were co-occurring with DBM and
TPM included major mutations like- M46IL, I54MV,
I84V, L90M, N88S, V32I, I47V, V82AS, D30N, G48V;
and accompanied by minor mutations like- L10I, I13V,
L63P, A71V, L89M, I93L, E35DN, I15V, D60E, L24I etc.
We have studied the structural roles of these mutations
at molecular levels with the aid of molecular dynamics
simulations of the wild type and mutant HIV-1 PRs in
their unbound NFV-bound docked complexes. Molecu-
lar dynamics simulation has become one of the most
important tools in the theoretical study of biological
molecules. This computational approach calculates the
time dependent behavior of a molecular system and can
provides even minute details related to fluctuations and
conformational changes that may occur in the protein
structure. This method is now being used routinely to
investigate the structure, dynamics and thermodynamics
of biological molecules and their complexes [17,18]. The
protease-ligand (NFV) interaction energies were calcu-
lated for wild type and mutant proteases using MM/
GBSA approach. Similar kind of studies on other biolo-
gical systems reporting the underlying molecular
mechanisms of drug resistance have been successfully
carried out and reported before and have provided valu-
able insights into the comparative mode of interactions
of drugs with mutants and wild type proteins [19-25].
Materials and methods
Preparation of wild type and mutated HIV-1 protease
structures
The crystal structure of protease-NFV complex (PDB:
1OHR) [26] was downloaded from the Protein Data
Bank [27] and was pre-processed using ViewerLite, a
visualizing tool from Accelrys (Accelrys, Inc., San Diego,
CA, USA). The ligand NFV and the water molecules
were removed from the structure and the protein was
further prepared and optimized using Schrödinger’s pro-
tein preparation wizard [28,29]. The residues V77 and
L33 were mutated to isoleucine and phenyalanine to
obtain double mutant DBM (Figure 1A) through the
protein preparation wizard. Similarly triple mutant TPM
(Figure 1C) was obtained by mutating residues V77, L33
and K20 to isoleucine, phenylalanine and threonine
Table 1. Number of subtype-b clinical isolates reported in
HIV drug resistance database
MUTANT NAME MUTATION SET ISOLATES
DBM V77I-L33F 407
TPM V77I-L33F-K20T 16
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respectively. The preparation of structures involved
addition of hydrogen bonds, creation of disulfide bonds,
removal of bad contacts, capping of protein terminals,
optimization of bond lengths, conversion of selano-
methionine to methionine and cleaning the geometry of
overlapping residues. Side chain prediction and refine-
ment of selected residues was carried out using PRIME
module of Schrodinger (Prime, version 2.1, Schrödinger,
LLC, New York, NY, 2009). The study of flap move-
ments is crucial to understand and compare the molecu-
lar dynamics of wild type and mutants HIV-1 PR. In the
ligand-bound crystal structure, the flap residues were
involved in interactions with the inhibitor or natural
substrate [30,31] while the flaps of unliganded protease
were found to be highly flexible [32]. To analyze the
flap motions of our mutants with respect to the wild
type protease, we selected the unliganded structure [33]
of HIV-1 protease [PDB: 1HVP]. The double (DBM_M)
and triple (TPM_M) mutants were prepared similarly to
the procedure described above.
The drug Nelfinavir (NFV) (CID 64143), was pro-
cessed before docking using LigPrep’s ligand preparation
protocol (Ligprep v2.5; Schrödinger, Inc.: Portland, OR,
2011). The three-dimensional coordinates (tautomeric,
stereochemical, ionizing variants) were generated along
with their energy minimization and flexible filtering.
Molecular dynamics simulations
MD simulations of the docked and unliganded complexes
(both wild type and mutant) were accomplished using
Desmond Molecular Dynamics system, with Optimized
Potentials for Liquid Simulations (OPLS) all-atom force
field 2005 [34,35] as described in some of our previous
studies [36-39]. The prepared protein molecules were
solvated in the presence of explicit solvent on a fully
hydrated model with TIP4P water model in a triclinic
periodic boundary box (distance between box wall and
protein complex was kept at 10 Å to avoid the direct
interaction with its own periodic image) to generate
required systems for MD simulations. The energy of pre-
pared systems for MD simulations was minimized to
5000 steps maximum using the steepest descent method
until a gradient threshold (25 kcal/mol/Å) was reached,
followed by L-BFGS (Low-memory Broyden-Fletcher-
Goldfarb Shanno quasi-Newtonian minimizer) until a
convergence threshold of 1 kcal/mol/Å was met. The
default parameters in Desmond were applied for systems
equilibration. The so equilibrated systems were then used
for simulations at 300 K temperature and a constant
pressure of 1atm, with a time step of 2fs. The long range
electrostatic interactions were handled using Smooth
Particle Mesh Ewald Method. Cutoff method was
selected to define the short range electrostatic interac-
tions. A cutoff of 9 Å radius (default), was used.
The prepared conformations of NFV were docked to the
stabilized mutants DBM and TPM using Glide docking
software [40,41]. We performed semi-flexible docking
where the ligand was made flexible keeping the receptor
macromolecule rigid. The flexibility of ligand molecule
gives it the freedom to search from six degrees of rotational
and translational freedom and an arbitrary number of tor-
sional degrees of freedom. A random perturbation to each
was applied at each time step, and the interaction energy
was evaluated for the new location and conformation.
A scoring grid was prepared on the active site of the
homodimer i.e. at the interface of both the subunits,
using receptor grid generation platform of Schrödinger
[40,41]. Keeping all the parameters default, a grid of size
20 × 20 × 20 Å with an inner box size of 10 × 10 × 10 Å
was generated.
Calculation of binding energies using MM/GBSA
The binding free energy was calculated according to the
Generalized Born Model and Solvent Accessibility
method, using Prime MM/GBSA [42] (Prime version
2.1, 2009). NFV-docked protease structures were used
for calculation of free energy of the wild type and
mutant structures. The binding free energy ΔGbinding
was calculated using the following equation:
Gbinding = ER:L − (ER + EL) +GSA +GSOLV;
Where ER + EL is the sum of energies of unbound
ligand and receptor, and ER:L is the energy of the docked
complex. ΔGSA is the difference of surface area energy of
the protein-ligand complex and the sum of surface area
energies of protein and ligand individually. ΔGSOLV is the
difference in the GBSA solvation energy of the complex
and summation of individual salvation energies of protein
and ligand. Energies of the complex were calculated using
the OPLS-All Atom force field [35] and GB/SA conti-
nuum solvent model.
Hydrogen bond and hydrophobic interaction analysis
The hydrophobic interactions and H-bonds of the
docked complexes were analysed using the Ligplot pro-
gram [43]. The parameters defining the H-bonds
between ligand and the protein complexes were as fol-
lows: acceptor-donor atoms distances less than 3.3 Å,
hydrogen acceptor atom distances less than 2.7 Å and
an acceptor-donor angle of 90° or more. Ligand-bound
protease structures obtained from Glide and the MD-
stabilized representative structures from Desmond were
selected for carrying out interaction studies. A represen-
tative structure was prepared by averaging the coordi-
nates of various frames extracted from the most stable
region of the trajectory, which persisted until the end of
the simulation run.
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SYFPEITHI epitope prediction analysis
The human immune system proteins human leukocyte
antigens (HLAs) bind to the intracellular epitopes aris-
ing from digestion of viral proteins. HLAs are responsi-
ble for presenting these epitopes on the cell surface and
hence triggering an immune response against the virus.
Escape mutations hinder strong binding of HLA to the
epitopes and thereby assist in bypassing the immune
response. Epitope prediction was done using Syfpeithi
Database of MHC ligands and peptide motifs [44]. The
algorithm relies on the scoring of binding motifs. From
the first amino acid of the protein, its sequence is
divided into octamers, nonamers and decamers. The
score of each oligomer is then calculated according to
the summation of scores of individual amino acids. The
amino acids are scored based on their observed frequen-
cies. Most frequently occurring residues in the anchor
positions are given a value 10, followed by a value of
8 given to the residues occurring in significant number
of ligands. Likewise, residues regarded unfavorable for
binding have a coefficient of -1 to -3. We have used
MHC class HLA-A3 for our analysis.
Calculation of volume and surface area of HIV-1 PR cavity
We used CASTp server [45] to estimate the cavity
volume and surface area of wild type and mutant pro-
teases. CASTp works on the principles of Alpha Shape
Theory [46] for detection and measurement of pockets in
a protein which are inaccessible to the solvent outside.
A probe of radius 1.4 Å was used for cavity measurement.
Results and discussion
Molecular dynamics simulations and energy stabilization
of unliganded wild type, DBM and TPM protease
To study the structural changes in closed conformation
of HIV-1 PR due to mutation we have considered the
NFV-docked crystal structure of HIV-1 PR. NFV was
removed before mutating the residues and then MD
simulations of unliganded wild type, double and triple
mutants were carried out for 20 ns. The Root Mean
Square Deviation (RMSD) of DBM and TPM were
found to be more stable with respect to that of wild
protease, with standard deviations of 0.28, 0.23 and 0.16
for wild type, DBM and TPM respectively (Figure 2). To
observe and compare the movement of residues, we
plotted the Root Mean Square Fluctuation (RMSF) plot
for both the subunits of the wild type and mutant pro-
teases (Figure 3). RMSF is a measure of average atomic
mobility of the backbone atoms during the MD simula-
tions. It was observed that the residues of DBM deviated
more from the wild type than that of TPM protease,
especially in chain A (Figure 3A). It was observed that
the flap residues (33-62) of the wild type protease were
more flexible in comparison to the mutants DBM and
TPM, indicating that there were relatively strong inter-
actions between the flaps of the mutants which made
them more stable in close conformation than the wild
type protease.
The representative structures from the MD simulation
trajectories of DBM and TPM were then selected for
studying their interactions with NFV. The mutants were
docked with all the stable conformations of NFV using
Glide and were compared with the NFV-docked crystal
structure of wild type HIV-1 PR.
Docking of NFV with wild type protease
The wild type protease showed a high affinity with NFV,
with an XP docking score of -9.32 Kcal/mol (Table 2). This
strong interaction was mediated by a number of hydropho-
bic interactions from both the chains of wild type proteases
and a hydrogen bond between Gly27 of A chain of pro-
tease with oxygen atom of NFV (Figure 4A, 5A). Prime/
MM-GBSA free binding energy of the wild type docked
structure was calculated to be -38.98kcal/mol. We com-
pared these interactions between NFV and wild type pro-
tease with the reference crystal structure of the protease. In
this case, stronger interactions were observed which were
accounted for by a large number of hydrophobic interac-
tions (Figure 5B) from both the chains of protease in addi-
tion to 4 hydrogen bonds. The catalytic site residues Asp25
(A) and Asp25 (B) were found forming hydrogen bonds
with NFV through their delta oxygen atoms. The delta oxy-
gen atom of Asp 30(A) was involved in forming a 2.90Å
long hydrogen bond with NFV, while the nitrogen atom of
NFV formed hydrogen bond with Gly27 (A) (Figure 4B).
Table 3 shows residues involved in hydrophobic interac-
tions in 1OHR and Glide docked structure.
Docking of NFV with DBM and energy stabilization of
NFV-DBM docked complex
Similar strategy was applied to study the binding interac-
tions of the two mutants DBM and TPM. The binding
affinity of NFV to DBM was found to be lowered with a
docking score of -8.04 Kcal/mol. The Prime/MM-GBSA
binding free energy of NFV-docked DBM was also found
to be significantly decreased by 27.90 Kcal/mol to -11.08
Kcal/mol (Table 2). Binding of NFV was mediated through
several hydrophobic interactions from both the chains of
DBM and also involved six hydrogen bond interactions
between protease and NFV (Figure 4C, 5C). These
H-bonds were formed by residues Gly27 (A), Asp29 (A),
Gly27 (B), Asp25 (B) and Asp29 (B) (Figure 4C). The
NFV-DBM docked structure was stabilized using molecu-
lar dynamics simulations of 10ns. The structure was found
to be stable throughout the simulations with a low RMSD
of 0.132 (Figure 2B). A decrease in the flexibility of flap
and active site residues was observed in NFV-bound DBM
as compared to the undocked DBM (Figure 6). The
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binding interactions were reduced to only four distant
hydrogen bonds and few weak hydrophobic interactions.
It was observed that the alignment of NFV also got per-
turbed, reducing its interactions with the cavity residues. It
was found that the hydrogen bonds were formed by active
site residues of B chain only which were Asp25(B) and
Gly27(B) (Figure 4D). The residues mediating hydrophobic
interactions before and after MD simulations are men-
tioned in Table 3.
Docking of NFV with TPM and energy stabilization of
NFV-TPM docked complex
The results of docking and simulations studies of triple
mutant TPM were notably different from other resistant
proteases and therefore justified its lower clinical pre-
sence with respect to DBM. The docking scores of NFV
with stable mutant TPM with NFV was found to be
-10.31 Kcal/mol. The Prime/MM-GBSA free binding
energy was stabilized by 3.68 Kcal/mol to -42 Kcal/mol
with respect to the wild type protease. This binding
involved five hydrogen bonds with residues Arg 8(A),
Asp 25(A), Ile 50(A) and Gly 48(B) along with a number
of hydrophobic interactions (Figure 4E, 5E). However,
the number of interactions got significantly reduced
after MD simulations. The NFV-TPM complex was
found to be stable throughout the simulations trajectory
with RMSD of only 0.183. The RMSF values of indivi-
dual residues were also found lowered with respect to
Figure 2 (A) RMSD trajectory of Wild protease, DBM and TPM during MD simulations. Trajectory for Wild protease (red line), DBM (green
line) and TPM (purple line). (B) RMSD trajectory of NFV docked DBM and TPM during MD simulations. Trajectory for DBM (green line) and TPM
(purple line).
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the undocked TPM. NFV was observed forming only two
hydrogen bonds which were made with Asp 25(A). From
this it becomes evident that the otherwise resistant K20T
mutation has the potential to reduce the resistance of
TPM in comparison to DBM (Figure 4F, 5F).
Possible intra-molecular interactions by V77I, L33F, K20T
and the neighboring residues, and their effect on cavity size
To further investigate the role of these clinically signifi-
cant mutations on the structure of the protease and to
understand the reasons behind the marked variation in
interactions and docking scores, the cavity size and
volume of the mutants and wild protease were studied.
The cavity volume and area were calculated at 0 ns, 5 ns,
10 ns, 15 ns and 20 ns of MD simulations (Table 4). The
pocket volume and surface area of wild type protease
(1OHR) were found to be 1186.1 Å3 and 705.9 Å2 respec-
tively. We analyzed the number of probable hydrogen
bonds formed by the mutated and their neighboring resi-
dues. Lys20 of both the wild type protease chains formed
two hydrogen bonds with their corresponding Ile13 resi-
dues. Leu33 formed hydrogen bonds with residues Leu76
and Gly78 of both the chains. Val77 formed two hydro-
gen bonds with Arg57 in both the chains.
V77I mutation in combination with L33F (DBM) dis-
played increase in the size of binding cavity (representa-
tive structure) with volume and area as 1375.5 Å3 and
732.10 Å2 respectively. This increase in cavity size is the
probable reason behind decreased binding affinity of
NFV to DBM (due to decrease in contact surface area
of ligand and active site residues). L33F mutation caused
positional change of neighboring residue Glu34, which
resulted in formation of an extra hydrogen bond
between Glu34 and Lys20 in DBM.
The binding pocket volume and area of the triple
mutant representative structure got reduced with
respect to the wild type protease, thereby increasing the
contact surface area between ligand and active site
Figure 3 Residue wise RMS fluctuations of Wild protease (red line), DBM (green line) and TPM (purple line). (A) chain A. (chain B).
Residues present in flap region are highlighted in blue.
Table 2. Docking score
Docking Score Wild DBM TPM
Glide XP -9.32 -8.04 -10.31
MM/GBSA(Kcal/mol) -38.98 -11.08 -42.66
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residues. The pocket volume and surface area of TPM
was found to be 1042.5 Å3 and 634.3 Å2 respectively.
Thr20 formed an additional hydrogen bond with Gly21
in B chain, whereas hydrogen bonds between 33rd resi-
due and Gly34 in B chain, and Leu76 in A chain were
lost as a result of mutations.
Comparison of flap movements of double and triple
mutant with the wild type protease
To study the effect of V77I mutation along with L33F
and K20T on the flap movements of HIV protease, we
considered the semi open modeled structure of HIV-1PR
(PDB:1HVP) [33]. The molecular dynamics simulation
was performed to view the flap opening mechanism of
mutants and compare them with the wild type protease.
The structure was processed and mutated as mentioned
before. The mutants of this protease structure are abbre-
viated as DBM_M (V77I, L33F) and TPM_M (V77I,
L33F, and K20T). The wild type and mutated structures
were stable throughout the simulations trajectory of 5 ns.
RMSD of DBM_M was found to be least (0.3) suggesting
its more stable nature in comparison to wild type (0.45)
Figure 4 Changes in the hydrogen bonds of NFV with protease before and after simulation. A. hydrogen bonds with wild protease in
Glide docked structure. B. in PDB structure 1OHR. C. hydrogen bonds with DBM before simulation and D. after simulation. E. hydrogen bonds
with TPM before simulation and F. after simulation. (Oxygen-Red, Nitrogen-Blue, Carbon-Grey)
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Figure 5 Changes in the hydrophobic interactions of NFV with protease before and after simulation. A. hydrophobic interactions with
wild protease in Glide docked structure. B. in PDB structure 1OHR. C. hydrophobic interactions with DBM before simulation and D. after
simulation. E. hydrophobic interactions with TPM before simulation and F. after simulation.
Table 3. Hydrophobic interactions
WILD PROTEASE
GLIDE DOCKED 1OHR
Arg 8(B), Leu 23(B), Gly 27(B), Asp 25 (A)(B), Ala 28 (A)(B), Asp 29(A)(B), Asp
30 (A)(B), Val 32(A), Ile 47(A), Gly 48(B), Ile 50 (B), Val 82(B), Ile 84(B)
Leu 23(B), Gly 27(B), Ala 28 (A), Asp 29(A), Val 32(B), Ile 47(B), Gly 48(B),
Gly 49(B), Ile 50 (A)(B), Val 82(A)(B), Pro 81(A)(B), Ile 84(A)(B)
DBM
GLIDE DOCKED After MD Simulation
Arg 8(A)(B), Ala 28(A)(B), Asp 30(B), Val 32(B), Ile 47(A), Gly 48(B), Gly 29(B),
Ile 50 (A)(B), Pro 81(A), Val 82(A), Ile 84(A)
Arg 8(A), Leu 23(A)(B), Gly 27(A), Ala 28 (A)(B), Asp 29(B), Asp 30(B), Gly
48(B), Ile 49(B), Ile 50(A), Ile 54(B), Thr 80(B), Phe 81(B), Ile 84(A)(B)
TPM
GLIDE DOCKED After MD Simulation
Gly 27(B), Asp 25(B), Ala 28 (B), Asp 29(B), Asp 30(B), Val 32(B), Ile 47(B), Gly
49(A)(B), Ile 50 (B), Thr 80(A), Val 81(A)(B), Ile 84(A)(B)
Leu 23(A), Gly 27(A)(B), Asp 25(B), Ala 28 (A)(B), Val 32(B), Gly 48(B), Val
82(B), Pro 81(A), Ile 84(A)
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and TPM_M (0.53). The RMSD trajectories of all the
three structures are shown in Figure 7. The RMSF plots
of both the chains were plotted for wild type, DBM_M
and TPM_M (Figure 8A, B). Though not much of a dif-
ference was observed between the mutants and wild type,
the B chain of DBM_M was found to be highly flexible
with the RMSF of flap residues reaching as high as 6.66
Å. This indicated wider opening of the flap residues of
DBM_M. To verify this proposal we calculated the dis-
tance between I50(A)-Ca and I50(B)-Ca atoms [47]. The
transition between semi open and open conformations of
protease flaps is characterized by interaction between I50
residues located on the tips of the flaps. The flaps of
DBM_M separated to the maximum distance of 26.8Å
between I50 Ca atoms, before 1 ns of simulation time
(Figure 9). This separation occurred early in wild type
Figure 6 Residue wise RMS fluctuations of NFV docked-DBM (green line) and TPM (purple line). (A) chain A (B) chain B. Residues present
in flap region are highlighted in blue.
Table 4
Binding cavity size and area
WILD
CAVITY 0 ns 5 ns 10 ns 15 ns 20 ns 1OHR
VOLUME (Å3) 1186.1 976.3 990.3 113.3 1097.3 1186.1
AREA (Å2) 705.9 612.3 734.6 739.645 645.3 705.9
DBM
CAVITY 0 ns 5 ns 10 ns 15 ns 20 ns Representative
VOLUME (Å3) 1156.0 790.6 1271.5 1403.2 1024.1 1375.5
AREA (Å2) 686.2 505.4 697.7 771.6 757.0 732.1
TPM
CAVITY 0 ns 5 ns 10 ns 15 ns 20 ns Representative
VOLUME (Å3) 1156.0 1257.8 938.3 820.2 801.2 1042.5
AREA (Å2) 686.2 753.9 554.8 572.9 498.5 634.3
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protease at around 400 ps with the separation of 25.7Å
between I50 Ca atoms. DBM_M and wild type protease
regained their semi-open open conformations after 1.13
ns. The closing of DBM_M after 2.03 ns is not in sync
with the wild type protease. The flaps of TPM_M showed
an entirely different trend throughout the simulation
time. They retained their closed to semi open state for
about 2.25 ns. This distance plot suggested that flaps of
DBM_M are more flexible in comparison to NFV-suscep-
tible wild type protease and less clinically prominent
Figure 7 RMSD trajectory of Modeled Wild protease, DBM_M and TPM_M during MD simulations. Trajectory for Wild protease (red line),
DBM_M (green line) and TPM_M (purple line).
Figure 8 Residue wise RMS fluctuations of modeled Wild protease (red line), DBM_M (green line) and TPM_M (purple line). (A) chain A.
(chain B). Residues present in flap region are highlighted in blue.
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TPM_M protease. The flap movements of wild type and
mutant proteases were visualized after specific time inter-
vals during the simulations and are depicted in Figure 10.
Putative selective mechanism of resistant mutations
Along with the selective pressure arising with anti-viral
treatment, immunological pressure has also been
reported as a sound theory behind the emergence of
resistant mutations in HIV-1 PR. This is also credible in
case of V77I mutation as it is located as an anchoring
residue in the epitope recognized by HLA-A3 [48], (non-
amer-LIGPTPVNI). The score representing probability of
binding and presenting of the peptide by HLA-A3 was
seen to be decreased to a small extent, suggesting that
the emergence of mutation V77I is preferentially due to
selective pressures imposed by anti-viral therapy, and less
likely due to immunological pressure.
Conclusion
The present study explains the molecular mechanisms
through which the V77I mutation in HIV-1 protease
cause resistance towards NFV. Since this is a non-active
site accessory mutation and clinically occurs with other
resistant mutants, we have considered two types of
mutant proteases double (DBM) V77I-L33F and triple
mutant (TPM) V77I-L33F-K20T in the study. NFV
showed a lower binding affinity towards DBM, and this
mutant was found to be more stable than the wild type.
The flap opening conformation of DBM_M suggested
wider separation of flaps and higher flexibility, thus
showing that the effect of mutation on the equilibrium of
closed and semiopen conformations of protease which
could be one reason behind the resistance showed by
DBM. Further, the increased cavity size of DBM
explained decreased binding affinity of NFV for the
Figure 9 I50/I50’ Distance plot in wild protease (red line), DBM_M (green line) and TPM _M (purple line).
Figure 10 Flap mutant of Wild protease (1HVP), DBM_M and TPM_M.
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mutant protease being accounted by reduced contact sur-
face area. TPM showed increased affinity towards drug
and this explains the reason behind its less clinical preva-
lence. The decreased pocket size and stable flaps sug-
gested that the combination of three mutations made
HIV-1 PR non-resistant towards NFV and hence would
not have been selected by nature. However the clinical
presence of these three mutations together suggests that
the mutant protease in nature may have been made resis-
tant due to the presence of other mutations.
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